|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,982.30 INR | -0.11% |
|
+0.63% | -0.60% |
| Jun. 25 | Dr. Lal PathLabs Expands Genomics Capabilities with New Sequencing System | MT |
| Apr. 28 | Nomura Adjusts Dr. Lal PathLabs' Price Target to INR3,560 From INR3,315, Keeps at Buy | MT |
Summary: Dr. Lal PathLabs Limited
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Highlights: Dr. Lal PathLabs Limited
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses: Dr. Lal PathLabs Limited
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 49.68 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings Chart: Dr. Lal PathLabs Limited
Source: Surperformance
ESG chart: Dr. Lal PathLabs Limited
Source: MSCI
| Fundamentals (Composite) | Global Valuation (Composite) | Financial estimates revisions (Composite) | Capi.($) | ||
|---|---|---|---|---|---|
| 2.91B | |||||
| 8.82B | |||||
| - | 4.3B | ||||
| 1.88B | |||||
| 1.29B | |||||
| 1.26B | |||||
| 1.23B | |||||
| Average | 3.1B | ||||
| Weighted average by Cap. |
Investor (Composite)
Trader (Composite)
ESG MSCI
BBB
Financials
Revenue growth
EPS growth
Capital Efficiency (Composite)
Net Margin
Financial Health (Composite)
Valuation
P/E
EV/Revenue
EV/EBITDA
PBR
Dividend Yield
Revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
Revenue revisions (1 month)
EPS revisions (1 year)
EPS revisions (4 months)
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (4 months)
Analysts' target price evolution (1 year)
Business Predictability
Surprise rates
Analysts' coverage
Analysts' recommendations divergence
Analysts' Target price divergence
Financial estimates divergence
ESG
Environment
Social
Governance
Controversy
Ethical controversies
Human rights controversies
Tax subsidies controversies
Sharia compliant
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- LALPATHLAB Stock
- Ratings Dr. Lal PathLabs Limited
Select your edition
All financial news and data tailored to specific country editions
